No Data
Express News | Sutro Biopharma Appoints DR. Barbara Leyman as Chief Business Development Officer
Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer
SOUTH SAN FRANCISCO, Calif., July 9, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug
Sutro Biopharma, Inc. (NASDAQ:STRO) Not Doing Enough For Some Investors As Its Shares Slump 28%
Unfortunately for some shareholders, the Sutro Biopharma, Inc. (NASDAQ:STRO) share price has dived 28% in the last thirty days, prolonging recent pain. The drop over the last 30 days has capped off
Institutional Owners May Take Dramatic Actions as Sutro Biopharma, Inc.'s (NASDAQ:STRO) Recent 17% Drop Adds to One-year Losses
Key Insights Given the large stake in the stock by institutions, Sutro Biopharma's stock price might be vulnerable to their trading decisions A total of 13 investors have a majority stake in the com
Express News | Vgxi Inc. Announces a Strategic Partnership With Sutro Biopharma Inc. to Support Growing Clinical Pipeline
Shareholders Will Likely Find Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Compensation Acceptable
TrytosaveabitOP amiable Llama_6295: Yes it is! I sold for like 17% green! And haven’t got back in yet! It’s on my “ update look at your notes “ list! That I was supposed to look at this past weekend! Hehehe. But got busy doing stuff around the house! Hehehe. GL
Arrayfunction : Interesting this news caused so much of a kerfuffle. Getting the participants and starting phase II means they still haven't proved it actually works yet
TrytosaveabitOP Arrayfunction: The early data suggests, so far anyway, that it could end up being the standard for care? But yes if. And it a long way from that. But this is how it moves forward
Arrayfunction TrytosaveabitOP: You are definitely correct there! It's crazy how much of bio-tech is effectively just setting money on fire and hoping for the best!
My thoughts were more around the high risk approach they are taking running phase II/III at the same time. That signals to me either they are extremely confident about the drug based on unreleased efficacy data and want to double-time on getting it to market or the company has decided it is closing its doors regardless of the outcome (so either getting a patent to sell or going bankrupt)
The 2nd one is a lot more likely given the mountain of extra red tape running simultaneously adds - so not going near it as a long investor. But I hope your king of swing style can get some good returns on it!